Minerva Neurosciences, Inc.
NERV$7M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaBURLINGTON
Drugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
NERV News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
Roluperidone 32 mg
Negative Symptoms of Schizophrenia
MIN-117 5.0 mg
Major Depressive Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Roluperidone 32 mg | Phase 3 | Negative Symptoms of Schizophrenia | - | - |
MIN-117 5.0 mg | Phase 2 | Major Depressive Disorder | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply